SCHEMBL1327181

SCHEMBL1327181

CC(C)OC(=O)CP(=O)(O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.42
TSHR P16473 3/20 0.40
MEN1 O00255 1/20 0.40
HPGD P15428 1/20 0.40
BLM P54132 1/20 0.40
KMT2A Q03164 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
ENO1 P06733 1/20 0.36
PGK1 P00558 1/20 0.35
PGK2 P07205 1/20 0.35
GRIN2D O15399 1/20 0.34
GRIN3B O60391 1/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2A Q12879 1/20 0.34
GRIN2B Q13224 1/20 0.34
GRIN2C Q14957 1/20 0.34
GRIN3A Q8TCU5 1/20 0.34
CYP2D6 P10635 2/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7836561 0.82 MEN1 (0.37) LMNATSHRMEN1HPGDBLM
SCHEMBL19347004 0.82 MEN1 (0.37) LMNATSHRMEN1HPGDBLM
SCHEMBL15257435 0.80 LMNA (0.38) LMNATSHRTDP1CYP2D6ALDH1A1
SCHEMBL5961220 0.80 LAP3 (0.37) LMNATSHRMEN1HPGDBLM
SCHEMBL3283984 0.77 LAP3 (0.38) LMNATSHRMEN1HPGDBLM
SCHEMBL29170733 0.77 LMNA (0.39) LMNATSHRCYP2D6ALDH1A1MAPT
SCHEMBL21122548 0.77 LMNA (0.39) LMNATSHRCYP2D6ALDH1A1MAPT
SCHEMBL8715424 0.77 LMNA (0.39) LMNATSHRTDP1CYP2D6ALDH1A1
Phosphoric Acid SCHEMBL31116634 0.76 LMNA (0.47) LMNATSHRMEN1KMT2ACYP2D6
SCHEMBL7514477 0.76 MEN1 (0.36) LMNATSHRMEN1HPGDBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117447355-A Preparation method of milbelin intermediate 南京威凯尔生物医药科技有限公司 2024-01-26 CN claimed
US-8058475-B2 Substituted cyclohexylmethyl compounds GRUENENTHAL GMBH (DE) 2011-11-15 US claimed
EP-1989174-B1 SUBSTITUTED CYCLOHEXYLMETHYL DERIVATIVES GRUENENTHAL GMBH (DE) 2011-08-03 EP claimed
US-20090286833-A1 Substituted Cyclohexylmethyl Compounds GRUENENTHAL GMBH (DE) 2009-11-19 US claimed
EP-1038900-B1 Double metal cyanide catalysts for the production of polyetherpolyols BAYER MATERIALSCIENCE AG (DE) 2004-07-14 EP claimed
US-6468939-B1 ESTERS OF PHOSPHORIC ACID, PHOSPHOROUS ACID, PHOSPHONIC ACID, PHOSPHONOUS ACID, PHOSPHINIC ACID OR PHOSPHINOUS ACID; COMPLEXING LIGANDS BAYER AKTIENGESELLSCHAFT (DE) 2002-10-22 US claimed
CN-115819216-A Preparation method of 10-hydroxy-2-decenoic acid 昆明博鸿科技有限公司 2023-03-21 CN disclosed
US-9908819-B1 Printing method for production a ceramic green body WZR ceramic solutions GmbH (DE) 2018-03-06 US disclosed
US-20160297829-A1 METHOD FOR PRODUCING AVENACIOLIDES AND USES THEREOF ACADEMIA SINICA (TW) 2016-10-13 US disclosed
CN-105829305-A NRF2 REGULATORS 葛兰素史密斯克莱知识产权发展有限公司 2016-08-03 CN disclosed
US-8901333-B2 Nanocrystals with functional ligands Life Technologies Corporation (US) 2014-12-02 US disclosed
US-8324222-B2 Cyclically substituted furopyrimidine derivatives and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-12-04 US disclosed
US-8058475-B2 Substituted cyclohexylmethyl compounds GRUENENTHAL GMBH (DE) 2011-11-15 US disclosed
US-4931591-A Novel 5-amino-4-hydroxyvaleryl derivatives CIBA-GEIGY CORPORATION (US) 1990-06-05 US disclosed
US-4727060-A HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1988-02-23 US disclosed
US-4570648-A Flavorants containing esters of 2,3,6,6-tetramethylcyclohexenyl carboxylic acids GIVAUDAN CORPORATION (US) 1986-02-18 US disclosed
US-4497830-A Carbacyclins, their preparation and pharmacological use SCHERING AKTIENGESELLSCHAFT (DE) 1985-02-05 US disclosed
US-4474687-A PERFUMES, FLAYORS GIVAUDAN CORPORATION (US) 1984-10-02 US disclosed
US-4375001-A ORGANOLEPTIC AGENT GIVAUDAN CORPORATION 1983-02-22 US disclosed
US-4133817-A 11-Oxa-prostaglandin analogs CHEMBRO HOLDINGS (PROPRIETARY) LIMITED (ZA) 1979-01-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297829-A1 METHOD FOR PRODUCING AVENACIOLIDES AND USES THEREOF COASY, ERG28, GSK3B LMNA 3114/4885TSHR 3168/4885MEN1 3715/4885
US-20090286833-A1 Substituted Cyclohexylmethyl Compounds CNR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R LMNA 1432/4885TSHR 760/4885MEN1 1779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.